Shanghai Pharmaceuticals Holding Stock Current Valuation
| 601607 Stock | 21.75 0.07 0.32% |
Valuation analysis of Shanghai Pharmaceuticals helps investors to measure Shanghai Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Shanghai Pharmaceuticals' Cash is projected to increase significantly based on the last few years of reporting. The current year's Total Cash From Operating Activities is expected to grow to about 5.5 B, whereas Total Cash From Financing Activities is forecasted to decline to about 1.7 B. Fundamental drivers impacting Shanghai Pharmaceuticals' valuation include:
Price Book 1.1371 | Enterprise Value 79.4 B | Enterprise Value Ebitda 9.0522 | Price Sales 0.2632 | Forward PE 18.4162 |
Fairly Valued
Today
Please note that Shanghai Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Shanghai Pharmaceuticals is based on 3 months time horizon. Increasing Shanghai Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Shanghai Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Shanghai Stock. However, Shanghai Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 21.75 | Real 20.95 | Hype 21.77 | Naive 21.83 |
The real value of Shanghai Stock, also known as its intrinsic value, is the underlying worth of Shanghai Pharmaceuticals Company, which is reflected in its stock price. It is based on Shanghai Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Shanghai Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Shanghai Pharmaceuticals Holding helps investors to forecast how Shanghai stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Shanghai Pharmaceuticals more accurately as focusing exclusively on Shanghai Pharmaceuticals' fundamentals will not take into account other important factors: Shanghai Pharmaceuticals Holding Company Current Valuation Analysis
Shanghai Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Shanghai Pharmaceuticals Current Valuation | 79.38 B |
Most of Shanghai Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Shanghai Pharmaceuticals Holding has a Current Valuation of 79.38 B. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.
Shanghai Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shanghai Pharmaceuticals by comparing valuation metrics of similar companies.Shanghai Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Shanghai Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Shanghai Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Shanghai Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Shanghai Fundamentals
| Return On Equity | 0.0641 | ||||
| Return On Asset | 0.0241 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 79.38 B | ||||
| Shares Outstanding | 2.79 B | ||||
| Shares Owned By Insiders | 65.61 % | ||||
| Shares Owned By Institutions | 13.27 % | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 0.26 X | ||||
| Revenue | 260.3 B | ||||
| Gross Profit | 28.41 B | ||||
| EBITDA | 9.62 B | ||||
| Net Income | 3.77 B | ||||
| Total Debt | 35.56 B | ||||
| Book Value Per Share | 19.13 X | ||||
| Cash Flow From Operations | 5.23 B | ||||
| Earnings Per Share | 1.08 X | ||||
| Price To Earnings To Growth | 10.53 X | ||||
| Target Price | 21.44 | ||||
| Number Of Employees | 48.16 K | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 71.71 B | ||||
| Total Asset | 211.97 B | ||||
| Retained Earnings | 33.82 B | ||||
| Working Capital | 40.06 B | ||||
| Net Asset | 211.97 B | ||||
| Last Dividend Paid | 0.41 |
About Shanghai Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.